Retatrutide Research Peptide Overview

Retatrutide (LY3437943) is a synthetic peptide designed to activate three key metabolic receptors: the GIP receptor (GIPR), GLP-1 receptor (GLP-1R), and glucagon receptor (GCGR). As a triple agonist research peptide, retatrutide creates a coordinated, multi-pathway model for studying energy homeostasis, hepatic lipid metabolism, and thermogenesis. It represents the next evolution beyond dual incretin agonists in metabolic peptide research.

What Is Retatrutide?

Retatrutide was engineered to engage three receptor systems simultaneously, each contributing distinct metabolic effects. Structural studies show that the peptide interacts with each receptor at different affinity levels: high affinity for GLP-1R (EC50 approximately 0.8 nM), moderate affinity for GIPR, and lower affinity for GCGR. This graded receptor activation profile is by design, as glucagon receptor engagement at lower intensity contributes to hepatic fat burning and thermogenesis while the incretin components support insulin release and glucose balance. Preclinical research has demonstrated that retatrutide activates three major signaling pathways: cAMP/PKA (enhancing insulin secretion), PI3K/Akt (improving glucose uptake), and AMPK (increasing energy utilization and fatty acid oxidation). Published studies have shown retatrutide’s effects on metabolic dysfunction-associated steatotic liver disease models (Sanyal et al., Nature Medicine, 2024), highlighting its unique multi-pathway metabolic coordination.

Retatrutide Mechanism of Action in Research

Retatrutide engages all three receptors as a unified signaling platform. At GLP-1R, it stimulates cAMP/PKA-mediated insulin secretion and POMC neuron activation for satiety signaling. At GIPR, it activates PI3K/Akt pathways in adipocytes, enhancing lipid uptake and insulin sensitivity. At GCGR, it promotes hepatic glycogenolysis, fatty acid oxidation, and thermogenesis through cAMP-mediated activation of lipase pathways and mitochondrial uncoupling. The synergistic interaction produces greater metabolic effects than activating any single or dual pathway. The glucagon receptor component specifically enhances energy expenditure, distinguishing retatrutide from dual agonists like tirzepatide.